Aclidinium bromide/formoterol fumarate vs Umeclidinium/Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanisms: Muscarinic acetylcholine receptor (M3) · Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide/formoterol fumarate · Duaklir Pressair
Rights held by Azurity Pharmaceuticals and partners; US product discontinued
NCT01437397 · Phase 3 · completed
This was a large randomized, quadruple-blind, placebo- and active-controlled trial with 1,692 randomized participants, using the regulator-accepted clinical lung-function measure FEV1 as its primary endpoint. Results were mixed: the 400/12 μg combination significantly improved post-dose FEV1 versus aclidinium and trough FEV1 versus formoterol, whereas the 400/6 μg combination did not significantly improve trough FEV1 versus formoterol (p=0.133).
Reported efficacy
Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate (Week 24, morning pre-dose (trough)); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) (met)
Result source: NCT03022097
Umeclidinium/Vilanterol
Marketed by GlaxoSmithKline and partners
NCT01777334 · Phase 3 · completed
The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.
Reported efficacy
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) (met)
Result source: NCT01777334
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aclidinium bromide/formoterol fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not reported | —Trial running · NCT06474039 |
| Trough FEV1, change | 0.1 vs -0.0+0.1 vs placeboNCT014373975 other results
| 0.2 vs 0.1vs TIONCT017773343 other results
|
| SGRQ total, change | -6.6 vs -2.2−4.4 vs placeboNCT014373974 other results
| —Trial running · NCT06474039 |
| TDI focal score | 2.0 vs 0.6+1.4 vs placeboNCT014373975 other results
| —Trial running · NCT06474039 |
Moderate or severe exacerbations, annualised rate
- Aclidinium bromide/formoterol fumarate
- —Not reported
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
Trough FEV1, change
- Aclidinium bromide/formoterol fumarate
- 0.1 vs -0.0+0.1 vs placeboNCT01437397
5 other results
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- Umeclidinium/Vilanterol
- 0.2 vs 0.1vs TIONCT01777334
3 other results
- 0.1 vs -0.0 NCT01899742
- 0.2 vs 0.2 NCT02487446
- 0.2 vs 0.2 NCT02487446
SGRQ total, change
- Aclidinium bromide/formoterol fumarate
- -6.6 vs -2.2−4.4 vs placeboNCT01437397
4 other results
- -5.9 vs -2.2 NCT01437397
- -7.2 vs -6.5 NCT01462942
- -8.3 vs -6.5 NCT01462942
- -8.7 vs -4.7 NCT03022097
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
TDI focal score
- Aclidinium bromide/formoterol fumarate
- 2.0 vs 0.6+1.4 vs placeboNCT01437397
5 other results
- 2.0 vs 0.6 NCT01437397
- 2.5 vs 1.2 NCT01462942
- 2.4 vs 1.2 NCT01462942
- 2.9 vs 2.1 NCT03022097
- 1.9 vs 1.9 NCT01908140
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Aclidinium bromide/formoterol fumarate: 4 of 4 rows · Umeclidinium/Vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aclidinium bromide/formoterol fumarate | Umeclidinium/Vilanterol |
|---|---|---|
| Dropout rate | 19.5%400/12 μga NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results18.3%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.9%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 14.1% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 8.8%400/12 μg NCT01462942 · Phase 3 10.5%400/6 μg NCT01462942 · Phase 3 32.4%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | 11.7%62.5/25 µga NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 6.9%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 6.2%400/12 μga NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results6.5%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.1%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 4.7% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 3.1%400/12 μg NCT01462942 · Phase 3 2.6%400/6 μg NCT01462942 · Phase 3 6.6%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | 4%62.5/25 µga NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 5.7%400/12 μga NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results5.4%400/6 μg NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.2%400/12 μg NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 7.5% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 6%400/12 μg NCT01462942 · Phase 3 4.7%400/6 μg NCT01462942 · Phase 3 9.7%400 μg/12 μg NCT01437540 · Phase 3 · registry result, not featured evidence 5%400/12 BID NCT03276078 · Phase 2 · registry result, not featured evidence | 3.5%62.5/25 µga NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 3.8% NCT02487446 · Phase 3 · registry result, not featured evidence 5%27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2.8%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 400/12 μga chronic obstructive pulmonary disease 15.2% (placebo 17.5%) cough 5.1% (placebo 3.6%) nasopharyngitis 4.8% (placebo 3.6%) NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 7 more results400/6 μg chronic obstructive pulmonary disease 14.7% (placebo 17.5%) nasopharyngitis 5.1% (placebo 3.6%) cough 3.9% (placebo 3.6%) NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg upper respiratory tract infection 11.8% (placebo 8.9%) chronic obstructive pulmonary disease 9.5% (placebo 13%) NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3 chronic obstructive pulmonary disease 15% headache 6% nasopharyngitis 5.6% NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg chronic obstructive pulmonary disease 8.6% (placebo 11.9%) nasopharyngitis 7.8% (placebo 7.2%) headache 7.5% (placebo 8.2%) NCT01462942 · Phase 3 400/6 μg chronic obstructive pulmonary disease 9.4% (placebo 11.9%) nasopharyngitis 7.9% (placebo 7.2%) headache 7.1% (placebo 8.2%) NCT01462942 · Phase 3 400 μg/12 μg chronic obstructive pulmonary disease 27% urinary tract infection 6.6% nasopharyngitis 6.4% NCT01437540 · Phase 3 · registry result, not featured evidence | 62.5/25 µga headache 8.8% nasopharyngitis 6.2% cough 2.9% NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 chronic obstructive pulmonary disease 10.6% nasopharyngitis 5.6% oropharyngeal pain 2.9% NCT02487446 · Phase 3 · registry result, not featured evidence 27.5/12.5 Bid chronic obstructive pulmonary disease 14.8% bronchitis 3.3% sinusitis 1.8% NCT02487498 · Phase 3 · registry result, not featured evidence 62.5/25 µg nasopharyngitis 7.3% headache 6.5% NCT01899742 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aclidinium bromide/formoterol fumarate
show 4 more results
show 5 more results
show 4 more results
show 1 more result
Umeclidinium/Vilanterol
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide/formoterol fumarate's landscape · Umeclidinium/Vilanterol's landscape